POLISCOPE
Back to feed
Part ofHeroin →

The civic record

Read. Follow. Verify.
High Impact

Congressional Hearing on the National Heroin Epidemic

Original title: AMERICA'S GROWING HEROIN EPIDEMIC

Record date · January 1, 2015

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Does

This document is a transcript of a 2015 House Judiciary hearing regarding the rising rates of heroin use and overdose deaths across the United States. Lawmakers and expert witnesses discussed the scope of the crisis and potential policy responses.

Why it matters

The hearing serves as a formal record of Congressional inquiry into the heroin epidemic, which informs future federal funding, drug enforcement strategies, and public health legislation.

Who It Affects

Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.

Directly affected

Public health officials

These officials are responsible for implementing strategies to address overdose mortality rates discussed in the hearing.

Directly affected

Law enforcement agencies

Agencies like the DEA are involved in the enforcement and policy strategies regarding heroin distribution.

Key Facts

  • The hearing took place on July 28, 2015, in the Rayburn Office Building.
  • The Subcommittee on Crime, Terrorism, Homeland Security, and Investigations held the hearing to address the national heroin epidemic.
  • Chairman Sensenbrenner reported a 72 percent increase in heroin-related deaths in Milwaukee County, Wisconsin, in 2014.
  • Six heroin overdoses occurred in Superior, Wisconsin, over a 6-day period in February 2015.
Show all 5 facts
  • The hearing included testimony from the White House Office of National Drug Control Policy, the Drug Enforcement Administration, and local prosecutors from Virginia and New Mexico.

Frequently Asked Questions

What was the purpose of this hearing?
The hearing was held to examine the growing heroin epidemic in the United States and gather information from federal officials and local prosecutors.
Who testified at the hearing?
Witnesses included the Director of the White House Office of National Drug Control Policy, the Acting Deputy Administrator of the DEA, and two local District Attorneys.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

temporal pattern90% confidence

Regional Spike Reporting

The hearing highlights a specific focus on localized data (Milwaukee and Superior, WI) to illustrate a national trend.

Connected Entities

House Committee on the Judiciary, Angela R. Pacheco, Nancy G. Parr and 3 more
OrganizationHouse Committee on the Judiciary“The committee overseeing the subcommittee”Map →
PersonAngela R. Pacheco“First Judicial District Attorney for Santa Fe, NM”Map →
PersonNancy G. Parr“Commonwealth's Attorney for the City of Chesapeake, VA”Map →
PersonJohn (Jack) Riley“Acting Deputy Administrator of the Drug Enforcement Administration”Map →
PersonF. James Sensenbrenner, Jr.“Chairman of the Subcommittee on Crime, Terrorism, Homeland Security, and Investi”Map →
PersonMichael P. Botticelli“Director of the White House Office of National Drug Control Policy”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy20
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz15
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record